Article Figures & Data
Figures
- Figure 1.
Study schema.
- Figure 2.
Overall-survival (OS) for the whole patient cohort. Median OS is 16.9 months (range=3.1-51.6 months) (95%CI=9.1 months to 20.3 months) in the nivolumab group, and the median OS is 19.2 months (range=1.0-28.3 months) [95% confidence interval (95%CI)=−6.6 months to not calculable (N/C)] in the pembrolizumab group.
- Figure 3.
Progression-free survival (PFS) for the whole patient cohort. Median PFS is 4.8 months (range=1.6-51.6 months) [95% confidence interval (95%CI)=2.8 months to not calculable (N/C)] in the nivolumab group. Median OS is 9.3 months (range=1.0-28.3 months) (95%CI=2.2 months to N/C) in the pembrolizumab group.
